Vivatides Therapeutics
PrivateLast Round
Series A
Apr 10, 2026
Total Funding Raised
$64M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Vivatides Therapeutics operates in Healthcare & Life Sciences and is based in Suzhou. Its latest recorded funding round was a Series A round in April 2026.
Vivatides Therapeutics is a biotechnology company that develops extrahepatic RNA-targeting therapeutics using a proprietary delivery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vivatides Therapeutics Comparables
Compare Vivatides Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Oligon Therapeutics | 73% | |
| Bicycle Therapeutics | 73% | |
| PeptiDream Inc. | 73% |
For institutional investors. Book with your work email.
Vivatides Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 10, 2026 | ||||
| Seed | Aug 22, 2025 |
For institutional investors. Book with your work email.
Vivatides Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HighLight Capital | Series A |
| TF Capital | Series A |
| Qiming Venture Partners | Seed, Series A |
| Apricot Capital | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 10, 2026
$54M round led by Qiming Venture Partners.
- Aug 22, 2025
$10M round led by Apricot Capital.
For institutional investors. Book with your work email.
Vivatides Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vivatides Therapeutics's valuation, stock price, and market status.
Is Vivatides Therapeutics a public or private company?
Vivatides Therapeutics is a private company.
What is the current stock price of Vivatides Therapeutics?
Vivatides Therapeutics is a private company, so its shares have no public market price. Caplight tracks Vivatides Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vivatides Therapeutics worth (valuation)?
Valuation information for Vivatides Therapeutics is not publicly available.
Can I buy Vivatides Therapeutics stock?
Vivatides Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vivatides Therapeutics's last funding round?
Vivatides Therapeutics's most recent funding round was Series A on April 10, 2026.
Who are the main investors in Vivatides Therapeutics?
Key investors in Vivatides Therapeutics include Qiming Venture Partners, Apricot Capital.
Will Vivatides Therapeutics IPO soon?
No public IPO plans have been announced for Vivatides Therapeutics.
How can I track Vivatides Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Vivatides Therapeutics's shares on secondary markets.